Please login to the form below

Not currently logged in
Email:
Password:

Pfizer/ S-A vaccines halted in Japan

Separate vaccines from sanofi-aventis and Pfizer have had their use suspended in Japan following the deaths of four children

Separate vaccines from sanofi-aventis (S-A) and Pfizer have had their use suspended in Japan following the deaths of four children.

S-A's ActHIB, to protect against Haemophilus influenzae type b, and Pfizer's Prevenar to prevent against pneumococcal disease such as pneumonia and meningitis, have been suspended by Japan's Health Ministry while the causes of deaths of four inoculated children are investigated.

According to the Associated Press, four children, age 2 years old or under, died between March 2 and March 4, with the deaths occurring within a three day period of the vaccines administration.

Over one million children have been inoculated in Japan since ActHIB was launched in the country in December 2008 and Prevenar started to be used in 2009.

The suspension follows a 2009 incident where authorities suspended the use of a batch of Prevenar in the Netherlands after the deaths of three children inoculated with the vaccine.

Authorities later decided there was no correlation between the deaths and the vaccinations.

7th March 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...